Navigation Links
OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation

Orexigen(TM) is evaluating zonisamide SR as a novel component in EMPATIC(TM) Phase IIb obesity trial

SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced results from a Phase I trial evaluating safety and pharmacokinetics of its novel, proprietary, sustained-release (SR) formulation of zonisamide. In the study, the SR formulation of zonisamide achieved a significant reduction in the incidence of spontaneous adverse events compared to an immediate release (IR), legacy formulation. Zonisamide SR is a key component in the Company's obesity product candidate Empatic(TM) and is presently being evaluated in a large, Phase IIb multi-center study.

The Phase I trial was a single-center, randomized, double-blind, single- dose, crossover study in 36 healthy, normal volunteers and compared legacy zonisamide IR to an equivalent dose of zonisamide SR. Adverse events were reported by 45.7% of subjects receiving the IR formulation versus only 8.5% receiving Orexigen's SR formulation. The most frequent overall adverse event was headache; six subjects receiving zonisamide IR reported headache, while none of those receiving zonisamide SR experienced headaches. As hypothesized by the Company when initiating the SR program, a relationship between adverse events and the peak free drug concentration (Cmax) of zonisamide was demonstrated. Across all subjects, zonisamide SR exhibited a lower Cmax than the legacy IR formulation, while retaining a similar overall exposure or area under the curve.

Results from a Phase II proof-of-concept trial evaluating Empatic formulated with zonisamide IR in combination with bupropion SR for the treatment of obesity were previously reported at the North American Association for the Study of Obesity (NAASO) in October 200 6. Empatic was associated with significant weight reduction through 48 weeks of treatment but also early discontinuations due to adverse events in approximately 37% of study participants. Zonisamide appeared to be the principal contributing factor, as a similar rate of discontinuations was evident among subjects receiving zonisamide IR therapy alone. Orexigen, in partnership with PharmaDirections, Inc. developed the proprietary SR formulation of zonisamide with the objective of improving its overall tolerability.

"We are excited that our novel, sustained release formulation of zonisamide was significantly better tolerated than the existing generic IR formulation. This is an important consideration in conditions such as obesity that often require longer-term maintenance therapy. Based on these results, we are eagerly awaiting the outcome of our ongoing 24 week Phase IIb multi-center study of Empatic, which incorporates our proprietary formulation of zonisamide SR," said Gary Tollefson, M.D., Ph.D., Orexigen's President and CEO.

About Orexigen(TM) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. For example, statements regarding the potential progress and results of clinical trials and the use of funds to support such trials may be forward looking statements. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Orexigen's business, including, without limitation: Orexigen's clinical trials may not proceed in the timeframes or in the manner Orexigen expects or at all; the results of earlier clinical trials may not be predictive of future results; the scientific theories relating to the central nervous system on which Orexigen has based its development programs may not result in product candidates with sufficient efficacy or safety to obtain regulatory approval or commercial success; Orexigen and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in Orexigen's public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


     Graham Cooper         Media:                        Investors:

     Orexigen CFO 
         Stephen Gendel                Jason Spark

     (858) 436-8600        (212) 918-4650                (619) 849-6005

CONTACT: Graham Cooper, Orexigen CFO, +1-858-436-8600; or Media, StephenGendel, +1-212-918-4650, or Investors, Jason Spark, +1-619-849-6005, bothfor Orexigen Therapeutics, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:OREX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  The fee-for-service reimbursement ... U.S. medical imaging is on its way ... care payer-provider contracts are set to phase ... wake, alter provider-vendor relationships. The shift to ... forward new purchasing frameworks in the medical ...
(Date:11/30/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a ... drug delivery systems, announced today it has signed definitive ... Incubator of Technologies Co., Ltd. ("HTIT") for exclusive rights ... China , Hong Kong ... were signed at the Israel Knesset (Parliament). ...
(Date:11/30/2015)... 30, 2015 iCAD, Inc. (Nasdaq: ... its latest solutions for advanced image analysis and ... at the Radiological Society of North American (RSNA) ... from November 29 to December 4, 2015. ... iReveal®, an automated breast density assessment solution, PowerLook® ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and ... unit extraction. These techniques and procedures have been in use for many years and ... While Dr. Parsa Mohebi, M.D. has utilized many of these methods over the years, ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the week of ... raise funds for its research, education, support, and advocacy efforts. The campaign is ... , The Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds ...
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... 30, 2015 , ... ChiliPad , Chili Technology’s temperature-controlled ... through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, recommends ChiliPad ... precisely regulates the surface temperature of each side of the bed so that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ ... NJ. He has both advanced training and considerable experience in reconstructive dentistry ... expert in cosmetic dentistry. He is an active Spear Education member providing ...
Breaking Medicine News(10 mins):